drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (allogeneic CAR γδ T cells)
drug_description
Allogeneic CD19-directed CAR-γδ T cell therapy; γδ T cells engineered with an FMC63-based CD19 CAR to mediate largely MHC-independent cytotoxicity and cytokine release against CD19+ B-ALL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic γδ T cells engineered to express a CD19-specific CAR (FMC63 scFv) bind CD19 on malignant B cells and, upon CAR signaling, execute largely MHC-independent cytotoxicity via perforin/granzyme release and cytokine secretion, leading to targeted lysis of CD19+ leukemia cells.
drug_name
QH10304-BAL-01
nct_id_drug_ref
NCT06696833